The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

The purpose of the study is to determine which combination works better in treating these types of lymphomas. Participants will be randomly assigned to one of the two treatment groups. The study will begin with a phase to ensure the safety and tolerability of the odronextamab and lenalidomide combination. Following this, the main phase will compare the two treatment combinations to see which is more effective in preventing the cancer from getting worse. This will be assessed by looking at how long participants live without their disease progressing, known as progression-free survival.

Throughout the study, participants will receive their assigned treatments and will be monitored regularly to assess the effects of the treatments and any side effects. The study is expected to last for several years, allowing researchers to gather enough information to make a clear comparison between the two treatment options. This research is important for finding better ways to treat follicular lymphoma and marginal zone lymphoma, potentially improving outcomes for patients with these conditions.

The purpose of the study is to evaluate how well the combination of Mosunetuzumab and Lenalidomide works in patients with relapsed or refractory Marginal Zone Lymphoma. Participants in the study will receive either the new combination treatment or a treatment selected by their doctor, which may include other medications like Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bendamustine, or Rituximab. Some participants may receive a placebo instead of the new treatment to compare the results.

The study will take place over several months, during which participants will receive their assigned treatment and be monitored regularly to assess the treatment’s effects on their cancer. The main goal is to see if the new treatment can help patients live longer without their cancer getting worse. Participants will have regular check-ups and tests to track their progress and any side effects they may experience. The study aims to provide valuable information that could lead to better treatment options for people with Marginal Zone Lymphoma.